Lack Or Loss Of Sexual Desire — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for lack or loss of sexual desire. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
1
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Lack Or Loss Of Sexual Desire

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sprout Pharms 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating lack or loss of sexual desire. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Addyi
FLIBANSERIN
 Sprout Pharms 1 75 — 2028-05-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7151103 Addyi method of use 75 2028-05-09

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7151103 Addyi method of use 75 2028-05-09

Related